Organometallic Ligands

4-[6-Amino-9-methyl-8-(triazol-2-yl)purin-2-yl]butan-2-ol is a synthetic chemical compound with potential applications in biomedical research. This compound is derived from purine, which is a molecule that plays a critical role in various biological processes, including the synthesis of nucleic acids. The presence of the triazole group in its structure enhances the compound's capacity for diverse chemical interactions, making it a versatile tool in experimental settings. Its mode of action is primarily based on its ability to mimic certain natural biological substrates or to act as an inhibitor in enzymatic reactions. By integrating into or disrupting normal metabolic and signaling pathways, this compound can be employed to study cellular responses or to unravel molecular mechanisms associated with specific diseases. Applications of 4-[6-Amino-9-methyl-8-(triazol-2-yl)purin-2-yl]butan-2-ol include the investigation of nucleotide interactions, research on enzyme kinetics, and exploration of potential therapeutic targets. Its unique structure and biochemical properties make it an intriguing subject for scientists aiming to advance the understanding of cellular processes and develop novel therapies.

The racemic mixture of cis-trans isomers of clomiphene citrate The cis-isomer, now termed zuclomiphene, is more estrogenic, while the trans-isomer, presently known as enclomiphene, is relatively anti-estrogenic. The racemic mixture utilized for ovulation induction typically contains 38% zuclomiphene and 62% enclomiphene.

S107 hydrochloride is a pharmacological compound that functions as a stabilizer of the ryanodine receptor (RyR), which is a crucial channel in the sarcoplasmic reticulum involved in calcium ion regulation within muscle cells. This synthetic molecule originates from medicinal chemistry efforts aimed at modulating intracellular calcium handling, particularly in skeletal and cardiac muscle tissues. The mode of action of S107 hydrochloride involves binding to the RyR, which reduces the pathological leak of calcium ions from the sarcoplasmic reticulum. This stabilization effect can enhance muscle function by maintaining optimal calcium homeostasis, which is essential for muscle contraction and relaxation cycles. The primary applications of S107 hydrochloride are in the research of muscle pathologies, including heart failure and muscle dystrophies, where dysregulated calcium handling plays a significant role. By improving calcium ion efficiency, S107 has been shown in various models to ameliorate symptoms of certain cardiac and skeletal muscle diseases, thereby serving as a promising tool for understanding and potentially treating these conditions in a laboratory setting.

Leucettine L41 is a small-molecule inhibitor, derived from marine sponge alkaloids, that targets dual-specificity tyrosine-regulated kinase-1A (DYRK1A) and related kinases. As a product originating from bioactive compounds isolated from the marine environment, its unique structure allows it to interact specifically with its target enzymes. The mode of action of Leucettine L41 involves potent inhibition of DYRK1A, an enzyme implicated in neurodegenerative diseases and cognitive disorders. By modulating the activity of this kinase, Leucettine L41 can influence phosphorylation processes that are critical in the regulation of neuronal function and plasticity. Applications of Leucettine L41 primarily focus on research into therapeutic strategies for conditions such as Alzheimer's disease, Down syndrome, and other cognitive disorders where DYRK1A is known to play a crucial role. Its specificity and efficacy make it an important tool in dissecting the molecular pathways involved in these diseases, facilitating the development of potential therapeutic interventions.

AP5 is a selective NMDA receptor antagonist, which is a synthetic compound with critical applications in neuroscientific research. This compound is derived from a series of structural modifications to achieve selective binding to the NMDA receptor. AP5 functions by competitively inhibiting the glutamate binding site on the NMDA receptor, thereby blocking the receptor's ability to allow calcium influx into the neuron. This action is essential for its role in studies investigating neural signaling, plasticity, and excitotoxicity. AP5 is extensively used in laboratory research to dissect the role of NMDA receptors in synaptic transmission and plasticity. By blocking NMDA receptor activity, it enables research into various neural processes, including long-term potentiation (LTP), synaptic plasticity, and neuroprotective mechanisms in models of excitotoxicity. Its applications extend to understanding neurodegenerative diseases, such as Alzheimer's and Huntington's disease, where excitotoxicity is implicated. AP5's utility in research extends our comprehension of fundamental neural mechanisms and aids in the development of therapeutic strategies targeting pathological neural signaling.

Gpr84 antagonist 8 is a small molecule inhibitor, which is synthetically derived, with a specific mode of action targeting the G protein-coupled receptor 84 (GPR84). This antagonist functions by inhibiting the receptor's signaling pathways, which are primarily associated with the modulation of inflammatory and metabolic processes. GPR84 is activated by medium-chain fatty acids and plays a significant role in immune cell regulation, particularly in monocytes and macrophages. The application of Gpr84 antagonist 8 is prominent in research settings aimed at understanding the pathophysiology of inflammatory diseases and metabolic disorders. By blocking GPR84, this antagonist can down-regulate pro-inflammatory cytokine production, offering potential insights into therapeutic strategies for conditions such as inflammatory bowel disease, diabetes, and other metabolic dysfunctions. Furthermore, Gpr84 antagonist 8 is instrumental in elucidating the receptor's role in various cellular and physiological contexts, making it a valuable tool for scientists exploring the intricate web of immune system responses.

Please enquire for more information about 18:1 (N12) Coenzyme A including the price, delivery time and more detailed product information at the technical inquiry form on this page

Inhibitor of PIP5K1C

Thalidomide-o-C8-COOH is a synthetic derivative of thalidomide, which is a modified compound used primarily in biochemical research. As a derivative of thalidomide, it is synthesized through chemical modification to include an octanoic acid moiety, resulting in a conjugated structure. The compound plays a significant role in the study of protein degradation pathways via the ubiquitin-proteasome system. The mode of action for Thalidomide-o-C8-COOH involves binding to cereblon, a component of the E3 ubiquitin ligase complex, thus influencing protein homeostasis by mediating the degradation of specific target proteins. Its ability to modulate protein interactions makes it useful for mechanistic studies related to targeted protein degradation, a vital process in cellular regulation and cancer research. Thalidomide-o-C8-COOH is leveraged in a variety of experimental frameworks, particularly in studying ligand-induced ubiquitination processes crucial for selectively degrading disease-relevant proteins. Its application extends to cancer biology, where researchers explore its potential for developing therapeutic strategies that exploit the ubiquitin-proteasome system for controlled protein degradation, providing insights into novel drug discovery and development pathways.

Endothelin receptor antagonist

Rivaroxaban is a natural drug that is a direct factor Xa inhibitor. It has been shown to be an effective therapy for the treatment of atrial fibrillation, deep vein thrombosis (DVT) and pulmonary embolism (PE). It works by inhibiting the enzyme, thrombin, which is responsible for the formation of blood clots. Rivaroxaban also has an effect on the coagulation system by decreasing the levels of fibrinogen and increases in antithrombin III. This drug does not have any specific antidote, but it can be reversed with heparin. Pharmacodynamics and drug interactions have been studied extensively in preclinical models, demonstrated by the concentration-time curves. Rivaroxaban is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready to use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

M 1145 is a monoclonal antibody, which is derived from a highly specific and engineered immunoglobulin source. Its mode of action involves targeting and modulating specific immune cell receptors, disrupting signaling pathways that are critical for the activation and proliferation of these cells. As a result, it can effectively modulate immune responses, making it a promising candidate for therapeutic applications in autoimmune diseases and certain types of cancers. In autoimmune conditions, M 1145's ability to suppress aberrant immune responses can reduce tissue inflammation and damage, offering potential for disease management and symptom alleviation. In oncology, it can be employed to interfere with the tumor microenvironment, potentially inhibiting tumor progression and enhancing the efficacy of other anticancer therapies. Studies on M 1145 are ongoing, focusing on its pharmacokinetics, bioavailability, and therapeutic index. Researchers are particularly interested in its integration into combination therapies where it could provide synergistic effects, enhancing the overall treatment outcomes. Overall, M 1145 represents a significant advancement in targeted immunotherapy, warranting further investigation in clinical settings.

Inhibitor of human neutrophil elastase

A light-sensitive probe that functionally encapsulates L-glutamate in an inactive form. Irradiation with light at 360-380 nm cleaves the MNI protecting group and allows the release of free L-glutamate.  It allows tuneable control of the L-glutamate in neurons and precise control over time, dose and location of L-glutamate release.

Please enquire for more information about Vortioxetine-d8 including the price, delivery time and more detailed product information at the technical inquiry form on this page

Platelet activating factor (PAF) inhibitor

Antagonist of NMDA glutamate receptor at glycine binding site

Nfat transcription factor regulator-1 is a biochemical reagent, which is commonly derived from synthetic or recombinant sources. It functions by modulating the activity of NFAT (nuclear factor of activated T-cells) transcription factors, which are crucial in several cellular processes. Through its regulatory action, it influences NFAT's ability to translocate to the nucleus and bind DNA, effectively controlling the transcription of genes involved in immune responses and other cellular activities. Nfat transcription factor regulator-1 is primarily used in research settings to study pathways related to immune function, inflammation, and cell differentiation. By modulating NFAT activity, scientists can elucidate the mechanisms by which immune cells, such as T-cells, are activated and how they contribute to various physiological and pathological processes. Its application is vital for advancing our understanding of immune system regulation, providing insights that could lead to therapeutic advancements in autoimmune diseases and other conditions involving dysregulated immune responses.

Thalidomide, propargyl is a derivative of the drug thalidomide, which is a synthetic immunomodulatory compound originally developed for its sedative and antiemetic properties. This molecule is sourced from chemical modifications of thalidomide, incorporating a propargyl group to enhance its biological activity profile. Its mode of action involves the modulation of immune responses, inhibition of angiogenesis, and possibly the epigenetic regulation of target genes. Thalidomide, propargyl exhibits potential applications in cancer therapy, owing to its ability to impact tumor microenvironments, specifically by inhibiting the formation of new blood vessels that are essential for tumor growth and survival. It serves as a significant focus in medicinal chemistry for the development of novel therapeutic agents aimed at combating malignancies and providing insights into the mechanisms of action of thalidomide analogs.

PXS 4728A is a small-molecule compound, which is derived from natural plant sources, acting as an activator of the sirtuin 6 (SIRT6) protein. SIRT6 is a member of the sirtuin family of NAD+-dependent deacetylases and ADP-ribosyltransferases, known to play a critical role in regulating metabolic processes, inflammation, and aging. The mode of action of PXS 4728A involves binding to and enhancing the activity of SIRT6. This interaction leads to the modulation of cellular metabolic pathways, thereby influencing glucose and lipid metabolism, DNA repair, and longevity-related processes. By activating SIRT6, PXS 4728A promotes the deacetylation of specific histone and non-histone proteins, resulting in altered gene expression patterns conducive to improved metabolic health and stress resistance. In the realm of scientific research, PXS 4728A is utilized extensively to explore its potential in the treatment of age-related diseases, metabolic disorders like type 2 diabetes, and conditions linked to chronic inflammation. Its ability to modulate key cellular processes makes it a promising tool in the study of therapeutic approaches aimed at enhancing healthspan and mitigating age-associated decline.